Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Dosing completed in phase I TTI-1612 study

May 17, 2013

Mirabegron/solifenacin as an effective therapeutic option for overactive bladder

May 16, 2013

Fedovapagon effectively reduces nocturia in men with BPH

May 15, 2013

Relypsa completes enrollment in pivotal phase III trial of patiromer

May 14, 2013

Astellas and Drais form new partnership to develop treatment candidate for nocturia

May 8, 2013

Roche patents new CYP11B2 inhibitors

April 22, 2013

Nymox's candidate for BPH shows promising sexual function profile in new study

April 18, 2013

Innovative 3D renal tissue model developed to investigate human disease and toxicity

April 18, 2013

FDA sets PDUFA action date for PA-21

April 16, 2013

Novel trypsin inhibitors for renal disorders patented by Astellas Pharma

April 11, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...